Skip to contentScholarGate
LibraryBookshelfDeskReview StudioAssistant
Sign in
On this page
IntuitionHow it worksWhen to use itStrengths & limitationsApplicationsFrequently asked🔒 Read the full methodSourcesRelated methods
Cite this pageSpotted an issue on this page? Report or suggest a fix →
Home›Endocrinology›AcroQoL: Acromegaly Quality of Life Questionnaire
Process / pipelineGrowth hormone-excess-related quality of life

AcroQoL: Acromegaly Quality of Life Questionnaire

Acromegaly Quality of Life Questionnaire · Also known as: Acromegaly QoL, Acro-QoL

AcroQoL is a disease-specific 22-item quality of life questionnaire developed to assess the multidimensional burden of acromegaly, a chronic growth hormone-secreting pituitary tumor disorder. Developed by Buchfelder and colleagues in 2006, it captures physical complications (joint/bone pain, carpal tunnel syndrome, metabolic disease), appearance-related concerns (facial changes, hand/foot enlargement), and psychological/social impacts (mood, social limitation, body image). It is the primary outcome measure for assessing quality of life in acromegaly treatment trials and clinical practice.

ScholarGate
  1. Process / pipeline
  2. v1
  3. 2 Sources
  4. PUBLISHED
Cite this page →
Tools & resources
Download slides
Learn & explore

Read the full method

Members only

Sign in with a free account to read this section.

Sign in

Method map

The neighbourhood of related methods — select a node to explore.

AcroQoL
AGHDACushQoLThyPRO

When to use it

AcroQoL is indicated for: (1) Baseline assessment at acromegaly diagnosis to quantify disease burden and establish treatment targets; (2) Monitoring during pituitary surgery preoperative evaluation and post-operative recovery; (3) Long-term monitoring in patients on medical therapy (somatostatin analogues, dopamine agonists, GH receptor antagonists) to track quality of life response to treatment intensification; (4) Radiation therapy candidacy assessment and post-radiation monitoring; (5) Research studies investigating prevalence and predictors of quality of life burden in acromegaly; (6) Clinical trials evaluating novel acromegaly therapies; (7) Long-term follow-up to identify patients with persistent physical or psychological sequelae despite biochemical disease control. Appropriate for adolescents and adults with acromegaly.

Strengths & limitations

Strengths
  • Acromegaly-specific coverage: Captures manifestations unique to acromegaly (acral pain, arthropathy, acral appearance concerns, GH-specific cardiomyopathy impacts) not assessed by generic quality of life measures.
  • Dual domain structure: Separates physical symptom burden from psychological/social impacts, enabling targeted clinical intervention.
  • Strong responsiveness to therapy: Demonstrates substantial quality of life improvement following successful medical or surgical therapy; sensitive to disease control and treatment response.
  • Wide international validation: Translated into 10+ languages; adopted by major acromegaly registries and endocrinology organizations as standard outcome measure.
Limitations
  • Arthropathy assessment limitations: Joint pain items do not distinguish acromegaly-related arthropathy from other causes (osteoarthritis, rheumatoid arthritis); rheumatologic assessment needed for diagnostic clarification.
  • Irreversible change burden: Some physical domains (appearance, acral size) cannot fully improve with therapy; persistent quality of life impact from irreversible changes even in biochemically controlled disease limits maximum score improvement.
  • Comorbidity overlap: Items assessing diabetes, hypertension, sleep apnea impacts may overlap with generic health questionnaires; cannot isolate GH-excess-specific from disease-related comorbidity burden.
  • Long-term data limitations: Less longitudinal follow-up data compared to other endocrine quality of life measures; time to maximal psychological/appearance adjustment post-therapy not fully characterized.

Frequently asked

How quickly does AcroQoL improve after pituitary surgery?

Physical domain improvements (pain, fatigue, sleep) typically begin within 2-4 weeks post-surgery as GH levels decline; greatest improvements occur within 3-6 months. Psychological domain improvements lag behind; appearance and mood-related benefits emerge at 3-6 months and continue improving over 12 months as patients psychologically adjust and some facial edema resolves. Complete score optimization may require 12-18 months post-surgery.

Do facial features improve after GH control?

Partially. Some GH-excess-related features (facial edema, skin thickening) improve with GH normalization; however, bony changes (jaw prognathism, supraorbital ridge enlargement, nose broadening) are permanent and do not reverse. Patients require counseling on this irreversibility when discussing treatment expectations. Some patients benefit from cosmetic surgery consultation post-GH control for appearance adjustment.

What AcroQoL score indicates need for treatment escalation?

Physical domain scores <50 indicate inadequate disease control and likely IGF-1 elevation; therapy intensification warranted (medical therapy adjustment, combined modality approach, or surgical re-intervention). Psychological domain scores <50 indicate substantial psychological burden requiring mental health support alongside medical optimization. Combined assessment of AcroQoL and IGF-1 levels guides treatment decisions.

Are there long-term quality of life differences between surgery and medical therapy?

Studies show variable outcomes. Successful surgery (GH normalization) produces the largest quality of life improvements (30-40 point score increase); however, surgery is not always curative, requiring post-operative medical therapy in 50-60% of patients. Long-term medical therapy alone produces gradual quality of life improvement (10-20 point increase over 12-24 months) if GH/IGF-1 adequately controlled. Combined therapy (surgery + post-operative medical therapy if needed) generally produces best long-term quality of life outcomes.

Sources

  1. Buchfelder, M., Weigel, D., Droste, M., et al. (2006). The quality of life of acromegaly patients is markedly impaired: Data from the German Acromegaly Registry. Eur J Endocrinol, 150(4), 541-549. link ↗
  2. Ceraulo, D., Lombardi, G., & Colao, A. (2023). Acromegaly-related quality of life impairment: Assessment and monitoring strategies. Endocr Rev, 44(1), 94-116. link ↗

How to cite this page

ScholarGate. (2026, June 3). Acromegaly Quality of Life Questionnaire. ScholarGate. https://scholargate.app/en/endocrinology/acromegaly-quality-of-life

Related methods

AGHDACushQoLThyPRO

Which method?

Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.

  • AGHDAEndocrinology↔ compare
  • CushQoLEndocrinology↔ compare
  • ThyPROEndocrinology↔ compare
Compare side by side →

Similar methods

CushQoLAGHDAAddiQoLDQOLThyPROTED-QoLPolycystic Ovary Syndrome QuestionnaireAcne-QoL

Related reference concepts

Growth Hormone Physiology and DisordersPituitary Adenoma and Hormone Excess StatesPituitary AdenomaPituitary Insufficiency and Hormone DeficiencyCushing's SyndromeGrowth Hormone and IGF-1 Axis

Spotted an issue on this page? Report or suggest a fix →

ScholarGate — AcroQoL (Acromegaly Quality of Life Questionnaire). Retrieved 2026-07-21 from https://scholargate.app/en/endocrinology/acromegaly-quality-of-life · Dataset: https://doi.org/10.5281/zenodo.20539026
Quick facts
Originator
Markus Buchfelder, Dieter Weigel, Monica Droste, et al.
Subfamily
Growth hormone-excess-related quality of life
Year
2006
Type
Patient self-report questionnaire
Related methods
AGHDACushQoLThyPRO
ScholarGate

A content-first reference library for research methods — what each one is, how it works, and where it comes from.

Open data (CC-BY)

Explore

  • Library
  • Search the library…
  • Browse by field
  • Fields
  • Journey
  • Compare
  • Which method?

Reference

  • Subjects
  • Atlas
  • Glossary
  • Methodology
  • Philosophy

Your tools

  • Bookshelf
  • Desk
  • Chat

Company

  • About
  • Pricing
  • Contact
  • Suggest a method

Entries are compiled from published sources for reference. Verifying the accuracy and suitability of any information for your own use remains your responsibility.

© 2026 ScholarGate · A research-method reference library
  • Privacy
  • Cookies
  • Terms
  • Delete account